- Home
- EWTX vs GNL Comparison
EWTX vs GNL Comparison
Compare EWTX & GNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- GNL
- Stock Information
- Founded
- EWTX 2017
- GNL 2011
- Country
- EWTX United States
- GNL United States
- Employees
- EWTX N/A
- GNL N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- GNL Real Estate Investment Trusts
- Sector
- EWTX Health Care
- GNL Real Estate
- Exchange
- EWTX Nasdaq
- GNL Nasdaq
- Market Cap
- EWTX 1.5B
- GNL 1.7B
- IPO Year
- EWTX 2021
- GNL N/A
- Fundamental
- Price
- EWTX $14.63
- GNL $7.15
- Analyst Decision
- EWTX Buy
- GNL Buy
- Analyst Count
- EWTX 9
- GNL 3
- Target Price
- EWTX $39.89
- GNL $9.00
- AVG Volume (30 Days)
- EWTX 723.3K
- GNL 1.9M
- Earning Date
- EWTX 08-07-2025
- GNL 08-06-2025
- Dividend Yield
- EWTX N/A
- GNL 10.62%
- EPS Growth
- EWTX N/A
- GNL N/A
- EPS
- EWTX N/A
- GNL N/A
- Revenue
- EWTX N/A
- GNL $789,545,000.00
- Revenue This Year
- EWTX N/A
- GNL N/A
- Revenue Next Year
- EWTX N/A
- GNL N/A
- P/E Ratio
- EWTX N/A
- GNL N/A
- Revenue Growth
- EWTX N/A
- GNL 38.85
- 52 Week Low
- EWTX $10.60
- GNL $6.51
- 52 Week High
- EWTX $38.12
- GNL $9.11
- Technical
- Relative Strength Index (RSI)
- EWTX 58.59
- GNL 38.29
- Support Level
- EWTX $13.34
- GNL $7.00
- Resistance Level
- EWTX $14.08
- GNL $7.22
- Average True Range (ATR)
- EWTX 0.57
- GNL 0.16
- MACD
- EWTX 0.16
- GNL -0.03
- Stochastic Oscillator
- EWTX 98.60
- GNL 19.23
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.